Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Anemia

Reblozyl Approved for Anemia in Beta Thalassemia

Diana Ernst, RPh

November 11, 2019

The FDA has approved Reblozyl (luspatercept–aamt; Celgene and Acceleron) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

General Hematology

Gene Therapy Gets Orphan Drug Status for Gaucher Disease

Diana Ernst, RPh

October 25, 2019

An investigational gene therapy has been granted Orphan Drug designation from the Food and Drug Administration for the treatment of Gaucher disease.

Thrombotic Disorders

FDA Approves Earlier Use of Nplate in Immune Thrombocytopenia

Diana Ernst, RPh

October 18, 2019

The FDA has approved the supplemental Biologics License Application for Nplate (romiplostim; Amgen) to expand treatment to newly diagnosed adult patients with immune thrombocytopenia.

Next post in Thrombotic Disorders

Diana Ernst, RPh

All articles by Diana Ernst, RPh

Reblozyl Approved for Anemia in Beta Thalassemia

Gene Therapy Gets Orphan Drug Status for Gaucher Disease

FDA Approves Earlier Use of Nplate in Immune Thrombocytopenia

Study Compares Anticoagulants for Antiphospholipid Syndrome